EX9924-4473: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)

Last updated: N/A
Sponsor: N/A
Overall Status: Active - Recruiting

Phase

3

Condition

Stroke

Heart Attack (Myocardial Infarction)

Diabetes Mellitus, Type 2

Treatment

N/A

Clinical Study ID

TX240843
  • Ages 50-100
  • All Genders

Study Summary

Oral Semaglutide

Eligibility Criteria

Inclusion

  • Type II Diabetes, history of heart attack, stroke, CABG, coronary stent, and other cardiovascular qualifications
  • HbA1C 6.5-10%
  • No current use of GLP-1 medications

Study Design

Study Start date:
Estimated Completion Date:

Study Description

  • Anticipated to continue until 2025
  • 1:1 randomization of semaglutide or placebo

Connect with a study center

  • Northern Pines Health Center, PC

    Buckley, Michigan 49620
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.